A source-backed hub for peptide brand owners who need to understand product-search demand, FDA and Health Canada signals, trust questions, and SEO angles without crossing into product claims.
Peptide Growth Agency does not sell peptides. We help peptide, wellness, longevity, and research-focused brands with websites, SEO, compliant copy, email, and marketing systems.
How to use this hub
See what buyers and founders search around peptide names, trust, source, policy, and website clarity.
Follow FDA and Health Canada signals with dates and official source links.
Turn demand into education, trust pages, SEO briefs, and review-ready marketing copy.
Latest updates
U.S. FDA
FDA's July 23-24, 2026 Pharmacy Compounding Advisory Committee agenda includes BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon, and other peptide-related bulk substances.
Official sourceHealth Canada
Health Canada warned consumers about unauthorized injectable peptide drugs promoted online for anti-aging, weight loss, bodybuilding, injury recovery, sleep, mental focus, and wellness.
Official sourceHealth Canada
Health Canada told consumers to avoid fake or unauthorized GLP-1 products, including semaglutide and tirzepatide, and to buy prescription drugs only from licensed pharmacies.
Official sourceU.S. FDA
FDA announced intent to restrict GLP-1 APIs intended for use in non-FDA-approved compounded drugs and discussed misleading marketing claims.
Official sourceProduct intelligence library
Each page maps search intent, regulator signals, brand-risk notes, and content angles so we can build topical authority for founders searching around peptide categories.
High search demand with active regulator attention
Semaglutide remains one of the highest-visibility peptide-adjacent search topics. Brands should treat it as a trust, source, and regulatory-intelligence topic rather than a shortcut for aggressive product claims.
View intelligenceGLP-1 search intelligenceHigh search demand with compounding and counterfeit scrutiny
Tirzepatide searches create strong buyer-intent traffic, but the regulatory context is sensitive. Brands need precise claims review, source-backed education, and strong trust architecture.
View intelligenceEmerging GLP-1 search intelligenceHigh-interest emerging topic with strong compliance risk
Retatrutide is a high-curiosity search topic, but it requires especially careful marketing because FDA has called out unapproved-drug and compounding concerns in GLP-1 contexts.
View intelligenceCompounding advisory watchScheduled for FDA advisory committee discussion in July 2026
BPC-157 is a popular search term and a regulator-sensitive topic. FDA scheduled BPC-157-related bulk substances for discussion at the July 23, 2026 Pharmacy Compounding Advisory Committee meeting.
View intelligenceCompounding advisory watchScheduled for FDA advisory committee discussion in July 2026
TB-500 appears in active peptide-search demand and on the July 23, 2026 FDA PCAC agenda for TB-500-related bulk substances. Content should focus on source-backed updates and claims discipline.
View intelligenceCompounding advisory watchScheduled for FDA advisory committee discussion in July 2026
KPV-related bulk substances are included in the FDA PCAC July 2026 agenda. That makes KPV a useful news-intelligence page for peptide founders, not a place for unsupported product claims.
View intelligenceCompounding advisory watchScheduled for FDA advisory committee discussion in July 2026
MOTS-c is a longevity-search topic with compliance sensitivity. FDA scheduled MOTS-c-related bulk substances for discussion at the July 2026 Pharmacy Compounding Advisory Committee meeting.
View intelligencePeptide search-risk clusterHigh search interest with peptide-related safety-risk context
CJC-1295 and ipamorelin searches sit in a high-interest, high-trust area. Brands should focus on careful education, source review, and clear boundaries around claims.
View intelligenceCosmetic and wellness search clusterPopular beauty and peptide search term with claims-review needs
GHK-Cu sits closer to cosmetic and beauty-search language, but peptide claims still need review. Brands can win with clean education, ingredient clarity, and restrained copy.
View intelligenceCompounding advisory watchScheduled for FDA advisory committee discussion in July 2026
Semax-related bulk substances are scheduled for discussion at the July 24, 2026 FDA PCAC meeting. Content should stay source-backed and avoid cognition or treatment claims.
View intelligenceCompounding advisory watchScheduled for FDA advisory committee discussion in July 2026
Epitalon is a longevity-search topic with regulatory sensitivity. FDA scheduled Epitalon-related bulk substances for discussion at the July 24, 2026 PCAC meeting.
View intelligenceB2B search intelligenceCommercial keyword cluster with trust and compliance pressure
Peptide wholesale searches often mix supplier, sourcing, quality, and price intent. The winning content strategy is trust-heavy, source-backed, and careful about product claims.
View intelligence